United States Securities and Exchange Commission · EDGAR
Accession 0001610315-26-000008
Oxeia Biopharmaceuticals, Inc.
Nature of amendmentExhibit image size fix
A
The Offering
as disclosed in this filing
Other (Series CF Preferred Stock)
$0.79
$20,000
$4,999,999
July 6, 2026
22 days remaining
$0max $4,999,999
Target is 0% of the maximum. Over-subscriptions accepted.
B
Financial Condition
two fiscal years, as filed
Pre-revenueBurn increasingDebt / assets 4867%2 employees
| Line item | Most recent FY | Prior FY | Δ |
|---|
| Revenue | 0 | 0 | — |
| Cost of goods sold | 0 | 0 | — |
| Net income | (1,246,701) | (1,053,814) | ▼ burn |
| Total assets | 260,456 | 213,921 | ▲ 22% |
| Cash & equivalents | 2,905 | 25,477 | ▼ 89% |
| Accounts receivable | 0 | 0 | — |
| Short-term debt | 12,676,450 | 7,951,988 | ▲ 59% |
| Long-term debt | 0 | 3,897,661 | ▼ 100% |
| Taxes paid | 0 | 0 | — |
Figures in USD as reported by the issuer. Securities offered in all 50 states.
C
Campaign Timeline
file 020-36726 · all filings under this campaign
Loading campaign history…